Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Telormedix

May 16, 2014
Telormedix’s Vesimune Successfully Completes Phase II for Carcinoma In Situ of the Bladder
Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder. More

December 2, 2013
Telormedix Raises CHF 6 M ($ 6.6 M) in Series B Financing Round
Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised CHF 6 Million in an extension to its Series B financing from existing investors Aravis Venture (Zurich, Switzerland) and Proquest Investments (Princeton, USA). More

August 7, 2013
Telormedix Receives EU Funding for the Development of a New Treatment for Psoriasis
Research consortium includes Biopta, Midatech Biogune, Molecular Profiles, and the USZ. More

January 7, 2013
Telormedix granted IND for Phase II in bladder cancer
Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has received FDA authorisation (IND: permission to use an investigational new drug in humans) for a Phase II trial of its lead product TMX-101, a TLR-7 agonist, in CIS (carcinoma in situ) in the bladder. More

June 4, 2012
Telormedix, Foamix Receive EU Funding for the Development of a New Topical Skin Cancer Treatment
Telormedix SA and Foamix Ltd., two clinical stage biopharmaceutical companies focused on TLR7 agonists in the treatment of cancer and inflammatory diseases and on topical foam delivery systems, respectively, today announced that they have raised funding from the European Eurostars Programme to coordinate a two-year international research project aimed at developing a new skin cancer topical treatment based on a foam formulation of one of the Company’s promising drug candidates, TMX-202. More

June 14, 2010
Telormedix’ TMX-101 commences clinical trial for bladder cancer
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). More

May 4, 2010
Telormedix appoints chief financial officer
Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced that it has appointed Phillipe Lutz as its new Chief Financial Officer. More

September 30, 2008
Telormedix raises 21 Mio CHF in Series A financing
Telormedix SA, a leader in novel immunotherapeutic molecules , has announced the closing of its first Series A equity investment round raising 21 Mio CHF (€13.1 million, $19 million), one of the largest Series A round in Switzerland for a biotech company in 2008. More

Data


26,442
Tech investments
From our Online Data Service
17,073
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 6€9.3MSoftware development
Dec 6€1.5MConsumer applications
Dec 6€3.7MInternet commerce
Dec 5€8.0MNanotechnology
Dec 5€11.0MBiotechnology
Dec 5€11.0MRobotics
Dec 5N/ARobotics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.